Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. May 21, 2014; 20(19): 5708-5720
Published online May 21, 2014. doi: 10.3748/wjg.v20.i19.5708
Table 1 Guidelines for treatment of resistance
Resistant drugAASLD 2009[18]EASL 2012[16]APASL 2012[17]KASL 2012[13]
LMVAdd ADV or TDF Stop LMV, switch to Truvada (TDF + FTC)Switch to TDF Add ADV (If TDF not available)Add ADV Switch to TDF Switch to IFN-based therapyAdd ADV or TDF Stop LMV, switch to ADV or TDF + other nucleoside analogues Switch to TDF Stop LMV, consider to switch with Peg IFN
ADVAdd LMV Stop ADV, switch to Truvada Stop ADV, switch to or add ETVNA-naïve; Switch to ETV or TDF Prior LMV-resistance; Switch to TDF + a nucleoside analogueAdd LMV, LdT, or ETV Switch to TDF Switch to IFN-based therapyWith prior LMV resistance, -Stop ADV, switch to TDF + other nucleoside analogues -Add ETV 1mg ADV as a first-line therapy -Stop ADV, switch to TDF + other nucleoside analogues -Add other nucleoside analogue, if rtA181T, add ETV
ETVSwitch to TDF or TruvadaSwitch to TDF Add TDF Add ADV (If TDF not available)Add TDF or ADV Switch to IFN-based therapyAdd nucleotide analogue
LdTSame treatment as LMVSwitch to TDF Add TDF Add ADV (If TDF not available)Same treatment as LMVSame treatment as LMV
CLVSame treatment as LMV
TDFAdd ETV, LdT, LMV or FTC (LMV-naïve; Switch to ETV/ prior LMV-resistance; Add ETV)
Multidrug-resistanceCombination of a nucleoside and a nucleotide (preferably TDF)ETV + TDF Switch to IFN-based therapyTDF + ETV 1 mg ADV + ETV 1 mg
CommentUpdate is required especially for multidrug-resistanceRecommendation about IFN-based therapy is limitedRecommendation about TDF resistance is limitedRecommendation about TDF resistance and IFN-based therapy is limited